Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer-Reference-Cited by-同舟云学术

Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

Published:2019-10 Issue:2 Volume:8 Page:LMT12
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Tone Mari¹,Izumo Takehiro¹,Awano Nobuyasu¹,Kuse Naoyuki¹,Inomata Minoru¹,Jo Tatsunori¹,Yoshimura Hanako¹,Miyamoto Shingo²,Kunitoh Hideo²

Affiliation:

1. Department of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan

2. Department of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan

Abstract

Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt-2019-0001

Reference20 articles.

1. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials

2. Pembrolizumab for the treatment of non-small cell lung cancer

3. Atezolizumab in advanced non-small cell lung cancer

4. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

5. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer;Cancers;2023-11-21

2. Comparison of the effect of two-way evaluation model on the whole process management of PICC catheterization in patients with lung cancer;Asian Journal of Surgery;2023-06

3. The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma;Diagnostics;2023-05-05

4. Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma;Current Opinion in Oncology;2023-03-14

5. Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature;Therapeutic Advances in Medical Oncology;2023-01